High throughput screening market seen reaching $70.18 billion by 2035

Market Research Future projects the global high throughput screening market will grow from $30.21 billion in 2026 to $70.18 billion by 2035, driven by AI-enabled automation, precision medicine research and broader use of non-animal testing. CDMOs are emerging as the fastest-growing end-user segment as drugmakers outsource more screening work.

Why it matters: - High throughput screening is becoming a core tool in drug discovery as pharmaceutical companies push harder into precision oncology, rare diseases and other targeted therapies. - The shift toward AI-driven automation and alternative testing methods is reshaping how labs screen compounds, design assays and prioritize hits. - Faster adoption could lower discovery costs and shorten the path from early screening to lead optimization.

What happened: - Market Research Future projects the global high throughput screening market will rise from $30.21 billion in 2026 to $70.18 billion by 2035. - The forecast implies a 10.42% CAGR over the 2026-2035 period. - The market base was estimated at $27.42 billion in 2025. - The report was released June 8, 2026. - A free sample and full report are available from Market Research Future.

The details: - AI and machine learning are being embedded directly into screening workflows, including predictive hit-ranking tools. - The report says automated compound library testing has moved from a premium feature to a baseline expectation. - Venture capital backed the segment with more than $1.2 billion in disclosed funding for microfluidic ultra-high-throughput screening startups from 2023 to 2025. - CDMOs are the fastest-growing end-user segment, with a 12.62% CAGR. - Cell-based assays held the largest technology share in 2025 at 41.2%. - Ultra-high-throughput screening systems generated an estimated $4.6 billion in 2025 revenue. - Lab-on-a-chip and microfluidic platforms are the fastest-growing technology segment, at an 11.31% CAGR through 2035. - Label-free technology generated $3.1 billion in 2025. - Primary and secondary screening accounted for 49.7% of application revenue in 2025. - Target identification generated $5.8 billion in 2025. - Toxicology and ADME applications are the fastest-growing application segment, at a 12.74% CAGR. - Hit-to-lead optimization was valued at $4.2 billion in 2025. - Pharmaceutical and biotechnology companies were the largest end-user group in 2025, with 44.9% of revenue. - Academic and research institutes generated $5.4 billion in 2025. - CROs contributed $6.1 billion in 2025. - North America led with about 36.8% of global revenue in 2025, while Europe was the second-largest region at $7.9 billion. - Asia-Pacific was the fastest-growing region, with a 12.85% CAGR from 2026 to 2035 and 24.1% of global revenue in 2025. - The Middle East and Africa represented 3.8% of global revenue in 2025. - South America reached an estimated $1.76 billion in 2025 revenue.

Between the lines: - The market is being pulled by three forces at once: AI adoption, rising precision medicine spending and regulatory acceptance of non-animal alternatives. - The report says the FDA Modernization Act 2.0 is accelerating demand for 3D cell culture and high-content imaging platforms. - Outsourcing is becoming more important as drug sponsors look for scale and specialized screening infrastructure. - The competitive landscape is moderately concentrated, with a top-five revenue share near 48% and room for smaller microfluidic and software-focused players. - Recent company moves include Thermo Fisher Scientific’s AI-integrated high-content screening platform, Danaher’s $5.7 billion acquisition of Abcam, Agilent’s label-free biochemical assay platform, Tecan’s CDMO partnership and Sartorius’ live-cell screening system.

What’s next: - By 2030, the report expects self-optimizing platforms to design, run and interpret assay campaigns with minimal human intervention. - Microfluidic and lab-on-a-chip systems are expected to spread screening capability into smaller labs and CDMOs. - Reagents, consumables, software subscriptions and managed services are likely to become more important revenue drivers than instrument sales alone. - Sustainability pressures and lower-reagent workflows should continue to support adoption of next-generation screening platforms through 2035.

The bottom line: - High throughput screening is shifting from a specialized lab capability to an automation-first discovery platform, with AI, outsourcing and non-animal testing standards driving the next decade of growth.